Although the specific efficacy and safety in different kidney disease subtypes still require further clinical trials, current evidence supports SGLT-2 inhibitors as a multi-target renal protective agent with broad potential applications in the management of CKD (129). This evidence concerns the gene SLC5A2 and chronic kidney disease.